Archive | October, 2021

Come for the Pitch, Stay for the Relationship

14 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Bright-eyed entrepreneurs with big ideas and even bigger fundraising needs have joined Digital RESI throughout 2021 in hopes of meeting investors who are just as excited to meet them, and there’s no virtual meeting spot that brings the two together like the Innovator’s Pitch Challenge (IPC). Apply to pitch at DIgital RESI November by October 22!

The IPC provides opportunities for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Fundraising entrepreneurs use the IPC for exposure, connection, valuable feedback, and often, a conversation that leads to many more down the road. Investors use it for the same – the opportunity to hear from and connect with entrepreneurs, learn more about exciting technology, and advance deal-flow initiatives.

For these reasons, the IPC is one of the most popular and well-attended features of the Digital RESI conference series, but don’t take our word for it. See what investors have said about their participation and check out previous investors that have sat on IPC judging panels throughout 2021.

“It was a very economical use of time; the investors got to ask their important questions and the Innovators got a good idea of the most pressing questions from the investors point of view.”
William Kuziel, MedPro Investors
“The Pitch Sessions are a great opportunity to connect with startup CEOs and learn more about their work…It really has been an effective and efficient way to make connections, create deal flow and help startups raise money for their upcoming raises.”
Mayank Taneja, OSF Healthcare
“I look forward to LSN’s events because they provide an opportunity for our venture capital firm to find promising companies with exceptional technologies. The organization and technology platform make it very easy to hear numerous pitches from founders.”
Nat Brinn, VC23
“The Pitch Sessions were a great opportunity to engage with the CEO/Founders of very innovative Life Science startups. Despite the COVID-related transition from in-person to virtual meetings, the RESI team did an outstanding job organizing these sessions, ensuring that the live Q&A was very productive, and facilitating follow-up with these exciting companies.”
Gary Gershony, Life Science Angels / BayMed Venture Partners
Previous 2021 Investor Judges
Hamzeh Abdul-Hadi
Hikma Ventures		 Aiden Aceves
Vida Ventures		 Nuno Afonso
Apogee Ventures		 Brent Ahrens
Canaan Partners
Alexandra Amen
BridgeBio		 Richard Anders
Mass Medical Angels		 Bauke Anninga
M Ventures		 Marc Appel
Orange Grove Bio
Anjan Aralihalli
CTI Life Sciences Fund		 Aimee Barkway
Hadean Ventures		 Amine Benmoussa
Apogee Ventures		 Attila Berces
FastVentures
Sascha Berger
TVM Capital Life Science		 Randy Berholtz
Mesa Verde Venture Partners		 Reetika Bhardwaj
ARCH Venture Partners		 Ivneet Bhullar
Fusion Fund
Yoann Bonnamour
Mérieux Equity Partners		 Todd Brady
Brace Pharma Capital		 Nat Brinn
VC23		 Ivan Burkov
INKEF Capital
Cynthia Cai
Viva BioInnovator		 Valerie Calenda
Mérieux Equity Partners		 Anke Cassing
High-Tech Gründerfonds		 Jeremy Chang
BridgeBio
Benjamin Chen
Panacea Ventures		 Kenneth Chew
Vickers Venture Partners		 Poh Hui Chia
Vickers Venture Partners		 Chinmay Chinmay
BioIdeations
Elizabeth Cho-Fertikh
Meda Angels		 Michel Chu
Acorn Campus Taiwan		 Pablo Cironi
Caixa Capital Risc		 Barbara Clarke
Astia Angels
Darren Cooke
Life Science Angels		 Peter Crane
Outsized Ventures		 David Crean
Mesa Verde Venture Partners		 Ruchi Dana
Dana Group
Aldemar Degroot
Biogen		 Niels Emmerich
AbbVie Inc.		 Bettina Ernst
BERNINA BioInvest		 Jemima Escamilla
Research Corporation Technologies
Naomi Fried
Ambit Health Ventures		 Ryo Fujinami
Shinsei Capital Partners		 Robert Garber
7wire Ventures		 Gary Gershony
BayMed Venture Partners
Tom Gibbs
Debiopharm Innovation Fund		 Sam Goldberger
Ambit Health Ventures		 Gage Greening
Medical Technology Enterprise Consortium (MTEC)		 Bryan Grulke
Volcano Capital
Brian Hakim
MedtecX		 Elaine Hamm
Ascend BioVentures		 Z Haroon
Julz Co LLC		 Christopher Haskell, Ph.D.
Bayer
Michelle Ho
5AM Ventures		 Vivien Ho
Pear Ventures		 Alan Hochberg
Roche		 Dave Hood
Medical Technology Enterprise Consortium (MTEC)
Dmitrij Hristodorov
Forbion Capital Partners		 Adam Hunke
Banner Venture Group		 Tomoko Ishikura
Kicker Ventures		 Mishael Zohar
OrbiMed Advisors LLC
I-Chien Jan
Hukui Bio		 Allan Johnston
Synergy Ventures		 Rick Jones
BioAdvance		 Patrick Keenan
Prevail Partners
Faisal Khan
AstraZeneca		 John Kim
Aphelion Capital, LLC		 Kristin King
Boston Harbor Angels		 Merom Klein
Keiretsu Forum
Pascal Krotee
RiverVest Venture Partners		 Dmitry Kuzmin
4Bio Capital Partners		 Sebastien Latapie
Dynamk Capital		 Zachary Leach
Catalyst Health Ventures
Carla Lema Tomé
Otsuka Pharmaceutical		 Elliot Levy
DreamIt Health		 George Li
Proxima Ventures		 Yatong Li
Sixty Degree Capital
Xinhong Lim
Vickers Venture Partners		 Debbie Lin
Boehringer Ingelheim Venture Fund		 Don Lin
Guoqian Venture Capital Investment		 Henry Lu
China Merchants Capital
Benedikt Luhmann
VI Partners		 Marc Martin-Casas
Illumina Accelerator		 Tai Mei
Meda Angels		 Andy Merken
Burns & Levinson
Wouter Meuleman
Illumina Ventures		 Junaid Mian
SP8CEVC		 Sergio Montero
Start-Up Chile		 Walter Moos
Pandect Bioventures
Anesa Mulabecirovic
Hadean Ventures		 Kim Nearing
BVCF		 Justin Norden
GSR Ventures		 Cédric Odje
Debiopharm Innovation Fund
Michael O’Donnell
Life Science Angels		 Marion Paolini
Servier		 Nami Park
Life Science Angels		 Francoise Perron-Sierra
Servier
Dave Pinkowitz
AnPac Bio		 Rohit Pratap Singh
Xeraya Capital		 Mark Ralph
Boehringer Ingelheim Venture Fund		 Varun Ramdevan
Johnson & Johnson Innovation
iGan Partners Employees, Location, Careers | LinkedIn
David Ramos
iGan Partners		 Richard Reschen
MSD		 Stella Robertson
Bios Partners		 Mel Rothberg
Mira Life Science Ventures
Nikhil Sadhwani
Individual Angel		 Caroline Sai
Angels Santé		 Christina Salys
Intuitive Surgical		 Diana Saraceni
Panakes Partners
Barbara Schilberg
BioAdvance		 Steve Seuntjens
Personal Health Solutions		 Bryan Shao
Keiretsu Forum		 Niels Sharman
High-Tech Gründerfonds
Megan Shaw
Innovation Works		 David Siet
Amzak Health		 Mira Sirotic
Keiretsu Forum		 Catello Somma
TVM Capital Life Science
Jill Sorensen
Medical Technology Enterprise Consortium (MTEC)		 Adarsh Sowcar
NOVA		 Karen Spilizewski
RiverVest Venture Partners		 Mark Springel
Vida Ventures
Sanjay Srinivasan
Accent Advisors		 Eran Steinberg
Imaging Arts		 Kevin Sterling
Keiretsu Forum		 Weiyong Sun
Daiichi Sankyo
Ben Sun
Sand Hill Angels		 Haolin Sung
Chaperone Investment		 Gayathri Swaminath
GreenFire Bio, LLC		 Mayank Taneja
OSF Healthcare Ventures
Mark Tang
Good Health Capital		 Liz Todia
Mutual Capital Partners		 Gadi Toren
Robert Bosch Venture Capital		 Bill Trainor
Mutual Capital Partners
Robert Tucci
Texas Halo Fund		 Thomas Vogelsong
KYTO Technology and Life Science		 Tad Weems
Agilent Technologies		 Scott Weiner
Amzak Health
Travis Whitfill
Bios Partners		 Thierry Wurch
Ipsen S.A.		 Jonathan Yeh
Saisei Ventures		 John Yianni
Earlybird
Alicia Yin
6 Dimensions Capital		 Derek Yuan
LYFE Capital		 Yanxiang Zhou
Illumina Ventures		 Anthony Zlaket
UnityPoint Health Ventures

RESI-NOV-Banner-3050x-1050

LSN Global Fundraising Bootcamp Series: Branding & Messaging for Fundraising

14 Oct

By Gregory Mannix, Vice President International Business Development, General Manager Europe, LSN

Join us October 19, 10 AM EDT/16:00 CEST for a new edition of Life Science Nation (LSN)’s Fundraising Bootcamp series, co-organized by BioIndustry Park Silvano Fumero in Turin, Italy. The topic of focus will be the importance of communicating effectively when reaching out to potential investors and partners through clear and compelling branding and messaging.

sign-up-for-free

In our last joint event for Europe, one of the key takeaways was the need to go global in early-stage fundraising. We highlighted the fact that global funding in the life sciences hit an all-time high in 2020 and is continuing to break records in 2021, but the lion’s share of deals happened in the US, followed distantly by Asia and Europe. The LSN Investor Database shows that even for a European company, there are more potential investment firms from outside of Europe than from the actual old continent itself, illustrating the need to seek global partners.

Register today to learn more about how LSN is making the world of early-stage funding a smaller place by tearing down the barriers between cross-border connections and how you can start reaching a global audience.

Europe-Bootcamp-Webinar-Banner

RESI-NOV-Banner-3050x-1050

Crafting the Tale to Tell with Terra Bioworks

14 Oct

By Rory McCann, Marketing Manager & Conference Producer, LSN

What can often stand in the way of meaningful connection with investors is a company story, and what often stands in the way of crafting the tale you want to tell can be you. No one knows your story better than you do, which can make it difficult to tell it clearly and concisely to those who do not yet know you.

Dr. David Mead, CEO of Terra Bioworks knew all there is to know about his company and the great work they are doing, but with the help of Dennis Ford and the team at Life Science Nation, David was able to put his knowledge to work telling a meaningful story to investors interested in his company. Learn more about David’s experience with LSN’s branding and messaging team and how he leveraged this experience to make powerful connections at Digital RESI.

Do you want to put your own company story to the test? Register for Digital RESI November and save $100 on early bird rates until October 29.

RESI-NOV-Banner-3050x-1050

Hot Investor Mandate: Corporate Venture Arm of Large Company Actively Seeks Investment Opportunities Related to Longevity and Long Term Care

14 Oct

The corporate venture arm of a large company was founded in 2016 and since then has made 30 investments. One of the firm’s main focus areas is in the longevity space as well as long term care. Within this space, the firm is open to all four sectors. The firm currently has a $350M fund and focuses mainly on Series A and B rounds in the form of equity, but will occasionally look at Seed rounds or late-stage rounds as well on a case by case basis. The firm is open to global opportunities, with a focus in US and Israeli markets.

The firm focuses on longevity investments and are open to all four life science sectors within that space. The firm looks for companies that have healthcare platforms that relate to monitoring and managing chronic conditions, as well as long term care and care coordination platforms. The firm is also interested in fintech companies focused on the retirement space as well as health data companies where the firm can find sources of data for life insurance and underwriting services. The firm will invest in all 3 classes of medical devices. The firm is not interested in biomedical companies and they do not invest in pre-clinical or pre-prototype companies.

The firm is open to all types of management teams from any type of background. The firm does not lead investments and prefers to co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe VC Firm Specializes in Oncology Drug Development Companies, Investing Up to $10M in USA & Europe Technologies

14 Oct

A venture capital firm based in Western Europe is entirely specialized in and focused on investing in early-stage oncology drug development companies. For its most recent fund, the firm seeks to invest in an estimated 10 biotechnology start-ups in cancer treatment. Typical investments are made in equity and with an average ticket size of 10 million Euros over a period of 5 to 7 years. In addition, the firm seeks to invest 1-2 million Euros in promising academic cancer research projects over a period of 18 months with the aim to transition these projects to NewCo’s. The firm seeks a lead investor role in companies based in the Netherlands and Belgium, and a co-investor role in other regions. The firm prefers syndicated investments with like-minded investors with equal ticket sizes. The firm’s main focus is on European companies, although they will consider US opportunities.

The firm focuses on a wide spectrum of cancer treatment, including but not limited to small molecules, antibodies, gene therapy, cell therapy, and immunotherapy. The firm supports early-stage companies from incubator stage and preclinical through phase 1. The firm prefers to invest in companies that have underlying platform technologies.

The firm can support management teams by being operationally involved on an interim basis in companies based in the country of their headquarters, and will frequently set-up companies from scratch with the inventors. The firm can help refine the business plan, R&D plans and provide financial, IP, IT, legal, HR support. If needed, the firm will take up interim-management roles.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Single Family Office Invests in Series A and Later Financing Rounds, Interested in Pre-Clinical Therapeutics, Devices, and Diagnostics

14 Oct

A USA-based single family office is very flexible in terms of investment size they are generally looking to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. The firm prefers A round and later stage companies. Pre-A interest depends upon technology stage. The firm’s preferred geography is North America and Europe.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. The firm invests on an opportunistic basis in areas of intersecting technologies, such as nucleic acid-based drugs and delivery, regenerative medicine and cell-based therapeutics and other immune-directed  therapies. The firm generally will not consider single target small molecules, biosimilars or other technologies for which there is already multiple therapeutic options. The firm is looking for niche disease areas where disruptive therapeutics have the potential to be truly disease-modifying, not just provide symptomatic relief or palliative care. The firm typically is interested in preclinical stage assets that have well-developed animal model dossiers to Phase II or early Phase III stage assets.

 The firm’s investment mandate particularly focuses on “smart” clinical trial formats such as adaptive trials and Master Protocol trials for capital efficiency. For devices, the firm is looking for devices that address and perhaps substitute for a pharmacologic in a given therapeutic market, such as deep brain stimulation technologies and orthopedics. The firm is generally not interested in cardiovascular disease or diabetes.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Healthcare-Focused VC Firm in USA Invests Globally in Therapeutics, Devices, Diagnostics, Digital Health, with Opportunistic Outlook

14 Oct

An early stage healthcare focused venture capital firm headquartered in the East Coast USA invests in Pre-Seed, Seed and Series A rounds across all four life science sectors. The firm has a current fund of $50M that they are actively raising and investing out of. The typical check size ranges from $100K – $1.5M in the form of priced rounds, equity, SAFEs or convertible notes. The firm invests globally, with a focus on helping companies outside of the US get into the US market.

The firm seeks to make investments in all four life science sectors, and is agnostic to subsector and indication. The firm is looking to provide start-ups with capital as well as advisory and strategic input when needed. The firm is open to pre-clinical companies and is open to all three classes of medical devices.

The firm is open to all types of management teams including first time entrepreneurs and underrepresented groups. The firm likes to typically lead investments, and will seek a board seat, but is also open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →